The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study a...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Terragna, Carolina, Remondini, Daniel, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Patriarca, Francesca, Pezzi, Annalisa, Levi, Giuseppe, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, Tacchetti, Paola, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, Santacroce, Barbara, Borsi, Enrica, Brioli, Annamaria, Marzocchi, Giulia, Castellani, Gastone, Martinelli, Giovanni, Palumbo, Antonio, Cavo, Michele
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2015
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891075/
https://ncbi.nlm.nih.gov/pubmed/26575327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.5718
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים